It has also been reported that a combination of PARP inhibitors and β-lapachone, a natural quinone, exhibits synergistic anti-tumor activity against NAD(P)H:quinone oxidoreductase 1 (NQO1)-overexpressing cancers, such as non-small-cell lung cancer, pancreatic cancer, and breast cancer (112). This evidence concerns the gene NQO1 and breast carcinoma.